NCT07332650
Prospective Clinical Investigation to Evaluate the Safety and Effectiveness of Juläine™ in Improving Gluteal Skin Laxity in Adults.
StatusNot Yet Recruiting
PhaseNot applicable
SponsorNordberg Medical AB
Primary completion (estimated)
At risk: Primary completion moved at least 8 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Apr 2027 to Jan 2028 Show 5 more changesShow less
- Start date: Oct 2026 to Jun 2027
- Eligibility criteria expanded, about 91 words
- Study completion pushed from Jun 2027 to Jan 2029
- Secondary endpoints revised (7)
- Study description shortened, about 4 words
Notable Start date: Aug 2026 to Oct 2026v3 Show 5 more changesShow less
- Eligibility criteria expanded, about 260 words
- Enrollment target: 90 to 100
- Secondary endpoints: 3 to 7
- Study title revised
- Study description shortened, about 5 words
- Notable Eligibility criteria revised
- Secondary endpoints revised (3)
- Study title revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proportion of participants who achieve an improvement in gluteal skin elasticity
Timeframe: Baseline and 240 days after randomization
Secondary (7)
Mean change in overall skin elasticity
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by investigator
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by participant
Proportion of adverse events (AEs)
Incidence and severity of Adverse events in the first 30 days
Show 2 moreShow less
Incidence and severity of AEs up to 240 days.
Incidence and severity of AEs up to 480 days
Arms and interventions
Immediate-treatment groupExperimental
Delayed-treatment group (delayed-start control)Other
Devices: Poly-L-Lactic Acid (Juläine™)